Olink
GenomeWeb Top 40 Down 4 Percent in February, Tracking Broader Market
The Dow Jones Industrial Average was down 4 percent, while the Nasdaq was down 1 percent, and the Nasdaq Biotech Index was down 7 percent.
Olink Q4 Revenues Rise 32 Percent
The proteomics firm posted revenues of $57.9 million, up from $43.7 million in the year-ago period and above the consensus Wall Street estimate of $57.3 million.
Single-cell transcriptome sequencing and spatial omics technologies have helped pave the way for a traditionally genetics-focused crowd to pursue proteins.
GenomeWeb Top 40 up 4 Percent in January, Following Broader Upswing
SomaLogic, Exact Sciences, and Myriad paced the winners in January, while Olink, a new addition to the Top 40, led decliners.
Olink Prices $85M Public Offering
The offering consists of 4,250,000 shares offered by Olink and 1,581,028 shares offered by certain shareholders at a price of $20 per share.
Nov 10, 2022
Olink Q3 Revenues up 59 Percent
Aug 11, 2022
Olink Q2 Revenues up 55 Percent
May 12, 2022
Olink Q1 Revenues Rise 67 Percent
Feb 14, 2022